MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel BackingZacks Investment Research • 06/19/26
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza VaccineAccesswire • 06/18/26
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside AheadThe Motley Fool • 06/18/26
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval ConcernsZacks Investment Research • 06/17/26
Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?Zacks Investment Research • 06/17/26
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEOReuters • 06/17/26
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?24/7 Wall Street • 06/16/26
Moderna Surges On This Surprising FDA View For Its mRNA-Based Flu ShotInvestors Business Daily • 06/16/26
US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adultsReuters • 06/16/26
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028Accesswire • 06/16/26
Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch SyndromeAccesswire • 06/08/26
Wall Street hated these 15 stocks. Then their earnings proved the analysts wrong.Market Watch • 06/03/26
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo EbolavirusZacks Investment Research • 06/02/26